Evidence map›Paper›PMID 37439332›Full record

ArticleHaematologica2023

Modified carfilzomib dosing is associated with improved treatment responses and longer time on treatment in patients with multiple myeloma.

Abdullah M Khan, Kiatlyn Dvorak, Qiuhong Zhao, Naresh Bumma, Francesca Cottini, Srinivas Devarakonda, Elvira Umyarova, Nidhi Sharma, Don Benson, Ashley Rosko

Open access · goldAbstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Haematologica, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.3field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Abdullah M KhanDivision of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH 43210. Abdullah.Khan@osumc.edu.
Kiatlyn DvorakDivision of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH 43210.
Qiuhong ZhaoDivision of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH 43210.
Naresh BummaDivision of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH 43210.
Francesca CottiniDivision of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH 43210.
Srinivas DevarakondaDivision of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH 43210.
Elvira UmyarovaDivision of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH 43210.
Nidhi SharmaDivision of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH 43210.
Don BensonDivision of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH 43210.
Ashley RoskoDivision of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH 43210.
The Ohio State University · US

Funding

Translational Therapeutics Research Program (TT)P30CA016058 · NCI · OHIO STATE UNIVERSITY · PI Daniel G. Stover · 1985 to 2026
$132.3M
NCI NIH HHS P30 CA016058
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Multiple MyelomaAntineoplastic Combined Chemotherapy ProtocolsDexamethasoneHumansOligopeptidesTreatment OutcomecarfilzomibDexamethasoneOligopeptides

Identifiers

PMID37439332
PMCPMC10690893
OpenAlexW4384126555

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.